Tvardi Therapeutics (TVRD) EBITDA (2013 - 2026)
Tvardi Therapeutics (TVRD) posted EBITDA of -$7.1 million for Q1 2026, up 7.06% sequentially from -$7.6 million in Q4 2025, and down 61.94% YoY from -$18.5 million in Q1 2025.
Tvardi Therapeutics (TVRD) EBITDA (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported EBITDA for 14 years, with the latest figure at -$7.1 million in Q1 2026.
- Quarterly EBITDA fell 61.94% year-over-year to -$7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.4 million (down 5.11% YoY) and the FY2025 annual result came in at -$26.7 million, up 4.84% from the prior year.
- EBITDA improved to -$7.1 million in Q1 2026 per TVRD's latest filing, from -$7.6 million in the prior quarter.
- Over five years, EBITDA peaked at -$4.4 million in Q1 2025 and troughed at -$32.6 million in Q4 2023.
- A 5-year average of -$17.4 million and a median of -$10.8 million in 2024 frame the typical range for EBITDA.
- The widest YoY moves for EBITDA: up 85.52% in 2022, down 2021.44% in 2022.
- Over 5 years, EBITDA stood at -$31.3 million in 2022, then decreased by 4.15% to -$32.6 million in 2023, then jumped by 66.87% to -$10.8 million in 2024, then climbed by 29.76% to -$7.6 million in 2025, then rose by 7.06% to -$7.1 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$7.1 million, -$7.6 million, and -$5.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | -6.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.05 Mn |
| Dec 31, 2025 | -7.59 Mn |
| Sep 30, 2025 | -5.94 Mn |
| Jun 30, 2025 | -8.87 Mn |
| Mar 31, 2025 | -4.35 Mn |
| Dec 31, 2024 | -10.80 Mn |
| Sep 30, 2024 | -5.68 Mn |
| Jun 30, 2024 | -7.18 Mn |
| Mar 31, 2024 | -29.67 Mn |
| Dec 31, 2023 | -32.61 Mn |
| Sep 30, 2023 | -28.90 Mn |
| Jun 30, 2023 | -32.34 Mn |
| Mar 31, 2023 | -27.65 Mn |
| Dec 31, 2022 | -31.31 Mn |
| Sep 30, 2022 | -23.85 Mn |
| Jun 30, 2022 | -4.47 Mn |
| Mar 31, 2022 | -27.91 Mn |
| Dec 31, 2021 | -33.52 Mn |
| Sep 30, 2021 | -1.12 Mn |
| Jun 30, 2021 | -30.88 Mn |